SCHEMBL2993570

SCHEMBL2993570

COc1cc2c(nc1OC)c(-c1cc3c(CNCCCN4CCCCC4)ccnc3[nH]1)cn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.40
EGFR P00533 1/20 0.38
CCNT1 O60563 7/20 0.38
CDK9 P50750 7/20 0.38
TDP1 Q9NUW8 2/20 0.36
EHMT2 Q96KQ7 3/20 0.35
EHMT1 Q9H9B1 3/20 0.35
ACP1 P24666 1/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
JAK2 O60674 1/20 0.34
LCK P06239 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
CDK7 P50613 1/20 0.34
BTK Q06187 1/20 0.34
LRRK2 Q5S007 1/20 0.34
AURKB Q96GD4 1/20 0.34
PGK1 P00558 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2990952 0.94 IGF1R (0.40) IGF1RCCNT1CDK9JAK2LCK
SCHEMBL2986378 0.83 IGF1R (0.41) IGF1RCCNT1CDK9JAK2LCK
SCHEMBL2996917 0.82 IGF1R (0.45) IGF1RCCNT1CDK9JAK2LCK
SCHEMBL2991640 0.81 IGF1R (0.40) IGF1RCCNT1CDK9JAK2LCK
SCHEMBL2986604 0.81 IGF1R (0.44) IGF1RCCNT1CDK9JAK2LCK
SCHEMBL2985996 0.81 IGF1R (0.48) IGF1REGFRCCNT1CDK9JAK2
SCHEMBL2982560 0.81 IGF1R (0.48) IGF1REGFRCCNT1CDK9JAK2
SCHEMBL2995039 0.80 IGF1R (0.42) IGF1RCCNT1CDK9EHMT2TLR8
SCHEMBL5529651 0.80 CCNT1 (0.43) IGF1RCCNT1CDK9GSK3B
SCHEMBL2990022 0.80 IGF1R (0.40) IGF1REGFRCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 IGF1R 606/4885EGFR 560/4885CCNT1 327/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 IGF1R 606/4885EGFR 560/4885CCNT1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.